Physicians' Academy for Cardiovascular Education

Lessons from the biology of CETP inhibition

10' education - Aug. 2, 2022 - Prof. John Kastelein, MD, PhD - Amsterdam, The Netherlands

Video navigation menu

  • CETP inhibition, atherogenic lipoproteins and CHD risk 0:50
  • CEPT inhibition biology 4:02
  • Lessons from previous CETP inhibitor outcome trials 4:52

Transcript

Show transcript

Educational information

This presentation by Prof. Kastelein is first lecture of an educational series about CETP inhibitors.

Faculty

Prof. John Kastelein, MD, PhD – Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, The Netherlands.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant received from New Amsterdam Pharma.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: